Glutamine supplementation to prevent morbidity and mortality in preterm infants
Citation: Moe‐Byrne T., Brown J.V.E. & McGuire W. Glutamine supplementation to prevent morbidity and mortality in preterm infants. Cochrane Database of Systematic Reviews 2016, Issue 4. Art. No.: CD001457.
The available trial data do not provide evidence that glutamine supplementation confers important benefits for preterm infants.
Glutamine is a conditionally essential amino acid. Endogenous biosynthesis may be insufficient for tissue needs in states of metabolic stress. Glutamine supplementation may improve clinical outcomes in critically ill adults, and it is possible that it may also benefit preterm infants. This review aims to determine the effects of glutamine supplementation on mortality and morbidity in preterm infants.
Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence the prevention and treatment of malnutrition but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about prevention or treatment of malnutirition on the basis of this summary alone.
If you have found this summary helpful, please consider making a donation. If everyone who looked at our COVID-19 resources gave us just £2 per month, it would fund Evidence Aid’s life-saving work.